Therapy of B-Cell Acute Lymphoblastic Leukemia: An Evolving Landscape

Subject areas

This course counts toward the state boards and subject areas below.

Disclosure statements

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD/CPE activity. CME/NCPD/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME/NCPD/CPE content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and commercial interests:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Amir Fathi, MD, discloses that he has served as a consultant for AbbVie, Agios, Amgen, Astellas, Blueprint, Bristol Meyers Squibb, Celgene, Foghorn, Forma, Genentech, Ipsen, Kite, Kura, MorphoSys, Pfizer, Seagen, Servier, Takeda, and Trillium, and that he has received grants or research support from AbbVie, Agios, Bristol Myers Squibb, Celgene, and Servier.

i3 Health has mitigated all relevant financial relationships.